Philip Morris International Inc. Presents at Jefferies Virtual Reduced Risk Seminar
Regulatory News:
Philip Morris International Inc.’s (NYSE: PM) President Smoke-Free Inhalable Products and Chief Consumer Officer, Stefano Volpetti, and Vice President Global Scientific Engagement, Gizelle Baker, present today at the Jefferies Virtual Reduced Risk Seminar.
Presentations will focus on the science of smoke-free products and nicotine (Gizelle Baker), as well as how PMI is leading and transforming through innovation in smoke-free products (Stefano Volpetti).
Presentations and Q&A sessions are being webcast live, beginning at approximately 9:00 a.m. ET (The Science of Smoke-Free Products and Nicotine) and at approximately 11:00 a.m. ET (Leading and Transforming Through Innovation in Smoke-Free Products), at www.pmi.com/2024jefferiesrrp, and on the PMI Investor Relations App available at www.pmi.com/irapp. An archived copy of the webcast, together with presentation slides, will be available on the same site and the App.
Lesen Sie auch
Philip Morris International: Delivering a Smoke-Free Future
Philip Morris International (PMI) is a leading international tobacco company, actively delivering a smoke-free future and
evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company’s current product portfolio primarily consists of cigarettes and smoke-free
products. Since 2008, PMI has invested over $12.5 billion to develop, scientifically substantiate and commercialize innovative smoke-free products for adults who would otherwise continue to smoke,
with the goal of completely ending the sale of cigarettes. This includes the building of world-class scientific assessment capabilities, notably in the areas of pre-clinical systems toxicology,
clinical and behavioral research, as well as post-market studies. In 2022, PMI acquired Swedish Match – a leader in oral nicotine delivery – creating a global smoke-free champion led by the
companies’ IQOS and ZYN brands. The U.S. Food and Drug Administration has authorized versions of PMI’s IQOS devices and consumables and Swedish Match’s General snus as
Modified Risk Tobacco Products. As of December 31, 2023, PMI's smoke-free products were available for sale in 84 markets, and PMI estimates that approximately 33 million adults around the world use
PMI's smoke-free products. Smoke-free business accounted for approximately 37% of PMI’s total full-year 2023 net revenues. With a strong foundation and significant expertise in life sciences, PMI
announced in February 2021 its ambition to expand into wellness and healthcare areas and, through its Vectura Fertin Pharma business, aims to enhance life through the delivery of seamless health
experiences. For more information, please visit www.pmi.com and www.pmiscience.com.